Conversely, elevated adiponectin has been associated with adverse outcomes, including ischemic stroke [24] and poorer prognosis in CAD and heart failure cohorts; this pattern has been termed the “adiponectin paradox” [25, 26]. Here, ADIPOQ is linked to ischemic stroke.